GlassScriptPhysician profile
Andrew P Balbaugh
NPI 1265640411
$8,026.72
in general payments reported to CMS, 2019-2025
49 companies · $1,725 in 2025
The $1,725 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $729 · 2020: $750 · 2021: $1,029 · 2022: $954 · 2023: $1,163 · 2024: $1,678 · 2025: $1,725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,564.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,104.76 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $811.38 | 2021-2025 | Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $745.35 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Corium, LLC | $501.46 | 2022-2025 | Azstarys |
| Pfizer INC. | $405.28 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $376.61 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Lilly USA, LLC | $351.33 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $331.63 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Ironshore Pharmaceuticals INC. | $215.88 | 2021-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $188.91 | 2024-2025 | Auvelity |
| Grifols USA, LLC | $187.66 | 2023-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $182.36 | 2019-2025 | Trintellix, Elaprase |
| Collegium Pharmaceutical, INC. | $154.33 | 2025 | Jornay Pm |
| Novartis Pharmaceuticals Corporation | $116.59 | 2019-2023 | |
| Acadia Pharmaceuticals INC | $91.69 | 2025 | Daybue |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Balbaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.